

Special Issue

Pharmacometabolomics

Message from the Guest Editor

Pharmacometabolomics or pharmacometabonomics, subsets of the greater metabolomics field, is the study of how differences in metabolites in an individual or subset of the population can be used to predict their varied responses to a drug or medical intervention. Metabolomics profiles obtained prior, during or after a drug or medical intervention can provide predictive, prognostic, and pharmacodynamic response biomarkers to a drug or medical intervention. This Special Issue is devoted to the applications of pharmacometabolomics. Topics covered by this Special Issue will include (not exclusively): metabolomics from nonclinical or clinical drug studies, pharmacometabolomics studies that can differentiate gender or racial differences in a drug response, precision medicine studies that combine pharmacometabolomics with pharmacogenomics data, and pharmacometabolomics studies that include pharmacokinetics and pharmacodynamics information.


Guest Editor

Dr. Richard Beger

Division of Systems Biology, National Center for Toxicological Research, US Food and Drug Administration, Jefferson, AR 72079, USA

Deadline for manuscript submissions

closed (15 December 2019)



Metabolites

an Open Access Journal
by MDPI

Impact Factor 3.5
CiteScore 5.7
Indexed in PubMed




mdpi.com/si/19696

Metabolites

MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
metabolites@mdpi.com

[mdpi.com/journal/
metabolites](https://mdpi.com/journal/metabolites)





Metabolites

an Open Access Journal
by MDPI

Impact Factor 3.5
CiteScore 5.7
Indexed in PubMed



[mdpi.com/journal/
metabolites](https://mdpi.com/journal/metabolites)



About the Journal

Message from the Editor-in-Chief

The metabolome is the result of the combined effects of genetic and environmental influences on metabolic processes. Metabolomic studies can provide a global view of metabolism and thereby improve our understanding of the underlying biology. Advances in metabolomic technologies have shown utility for elucidating mechanisms which underlie fundamental biological processes including disease pathology. *Metabolites* is proud to be part of the development of metabolomics and we look forward to working with many of you to publish high quality metabolomic studies.

Editor-in-Chief

Dr. Amedeo Lonardo

Internal Medicine, Ospedale Civile di Baggiovara, Azienda Ospedaliero-Universitaria, 41126 Modena, Italy

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Biochemistry and Molecular Biology) / CiteScore - Q2 (Endocrinology, Diabetes and Metabolism)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 16.1 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the second half of 2024).